Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi : Regeneron's Libtayo Combo Extends Lung Cancer Patients' Lives In Phase 3 Study

09/20/2021 | 12:37am EDT


ę MT Newswires 2021
All news about SANOFI
01:44aSanofi India's Net Profit Soars in Q3
MT
10/26Second Dupixent« (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate sign..
PU
10/26PRESS RELEASE : FDA Advisory Committee Votes in -3-
DJ
10/26SANOFI : Sell rating from Deutsche Bank
MD
10/26PRESS RELEASE : BioNTech Plans to Initiate the Construction of an mRNA Vaccine Manufacturi..
DJ
10/26PRESS RELEASE : Evotec provides preliminary nine month financial results
DJ
10/25REGENERON PHARMACEUTICALS : Second dupixent (dupilumab) phase 3 eosinophilic esophagitis t..
AQ
10/25SANOFI : Regeneron's Second Late-Stage Inflammatory Disease Trial Meets Primary Endpoints
MT
10/25SANOFI : Regeneron's Dupixent Improves Swallowing in Late-Stage Study
MT
10/25Second Dupixent? Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Dise..
CI
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2021 37 460 M 43 465 M 43 465 M
Net income 2021 6 075 M 7 048 M 7 048 M
Net Debt 2021 8 894 M 10 320 M 10 320 M
P/E ratio 2021 17,8x
Yield 2021 3,85%
Capitalization 108 B 125 B 125 B
EV / Sales 2021 3,11x
EV / Sales 2022 2,84x
Nbr of Employees 99 412
Free-Float 88,4%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 85,65 €
Average target price 105,07 €
Spread / Average Target 22,7%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI8.83%124 649
JOHNSON & JOHNSON5.32%436 334
ROCHE HOLDING AG15.84%338 387
NOVO NORDISK A/S60.69%244 467
PFIZER, INC.17.22%244 227
ELI LILLY AND COMPANY47.15%225 231